
Anita Kambhampati, Centers for Disease Control and Prevention
Blanca Vargas, Michael E. DeBakey VA Medical Center
Mahwish Mushtaq, Michael E. DeBakey VA Medical Center
Hannah Browne, Centers for Disease Control and Prevention
Sara Perregaux, Centers for Disease Control and Prevention
Scott Grytdal, Centers for Disease Control and Prevention
Robert L Atmar, Baylor College of Medicine
Jan Vinje, Centers for Disease Control and Prevention
Umesh D. Parashar, Centers for Disease Control and Prevention
Aron J. Hall, Centers for Disease Control and Prevention

Only first 10 authors above; see publication for full author list.

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017-10-04, Pages S317-S317
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx163.741
Permanent URL: https://pid.emory.edu/ark:/25593/s6f7h

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.741

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed April 25, 2020 1:30 AM EDT
Conclusions. Vaccinated individuals were more likely than unvaccinated individuals to benefit from antiviral treatment. This finding warrants confirmation in other populations.


Anita Kambhammatti, PharmD,1,2 Blanca Vargas, MD,2,3 Vivienne Mashug, MD,1,4 Hannah Browne, BS,3,5 Sara Perreaga, BS,3,5 Scott Grytdal, MPH,3 Robert L. Atmar, MD,1 Jan Vinje, PhD,6 Umesh D. Parashar, MBBS,1 Aron J. Hall, DVM,7 Cristina V. Cardemil, MD,2 Benjamin Lopman, PhD8 and Maria C. Rodriguez-Barradas, MD,1,7 National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, 13Infectious Diseases Section, Michael E. DeBakey VA Medical Center, Houston, Texas, 13Infectious Diseases Section, Baylor College of Medicine, Houston, Texas, 13Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, 13Rollins School of Public Health, Emory University, Atlanta, Georgia, 13Section of Infectious Diseases, Michael E. DeBakey VA Medical Center, Houston, Texas, 13Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas

Session: 139. Adult Viral Infection
Friday, October 6, 2017: 12:30 PM

Background. Norovirus is the leading cause of acute gastroenteritis (AGE) outbreaks in the United States; however, little data exist on the burden of endemic norovirus disease among adults. Robust estimates of the norovirus disease burden among US adults are needed to inform assessment of potential norovirus vaccines, which are currently in development.

Methods. We conducted active surveillance for AGE at the Michael E. DeBakey VA Medical Center in Houston, Texas, from November 1, 2015 to November 30, 2016. AGE was defined as an acute illness associated with vomiting or diarrhea, lasting ≤ 48 hours, within the previous 10 days. AGE cases, along with 20 inpatient and 37 outpatient controls, were admitted to the hospital (patients). Patients without AGE symptoms in the prior 14 days were enrolled as controls. Demographic data and illness characteristics were collected from enrolled subjects, and stool samples were collected and tested using the FilmArray gastrointestinal panel. Norovirus-positive cases were confirmed by real-time RT-PCR and genotyped after sequencing of conventional PCR products.

Results. From November 1, 2015–November 30, 2016, 130 inpatient and 85 outpatient AGE cases were detected and confirmed as norovirus-positive. Among cases, 201 (93%) were male, and 94 (44%) were ≥65 years; median duration of illness was 3 days (range, 1–10 days). Norovirus was detected in 12 (9%) inpatient and 15 (18%) outpatient cases; norovirus was not detected in any controls. Incidence of norovirus-associated hospitalization was 151,000/100,000 population, and was similar in hospitalized cases aged <65 years (14/100,000) and ≥65 years; median duration of illness was 3 days (range, 1–10 days). Norovirus was positive in 12 (9%) AGE cases and 15 (2%) controls, with the highest incidence of norovirus in adults and importance of a norovirus vaccine.

Disclosures. R. L. Atmar, Takeda Vaccines, Inc.: Research Support, Research support. B. Lopman, HHS/NIAID: Grant Investigator, Grant recipient. Bill & Melinda Gates Foundation: Grant Investigator, Grant recipient.

1045. Norovirus, Astrovirus, and Sapovirus in a Tertiary Care Hospital Research Hospital Shelby Daniel-Wayman, BA1; Gary Fable, MT, SM2; Tara Palmore, MD3; Kim Green, PhD1 and D. Rebecca Prevots, PhD, MPH4; 1Epidemiology Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 2Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, 3Hospital Epidemiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland, 4Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Session: 139. Adult Viral Infection
Friday, October 6, 2017: 12:30 PM

Background. Norovirus, astrovirus, and sapovirus are known to cause acute gastroenteritis as [VA] Medical Center, which approximately 10,000 unique patients were seen each year. In this study, we aimed to highlight the burden of norovirus in adults and importance of a norovirus vaccine.

Methods. We identified patients with a positive BioFire FilmArray gastrointestinal panel result for norovirus, astrovirus, or sapovirus from September 15, 2015 through November 30, 2016. We reviewed patient medical records to abstract clinical and microbiologic information. Chronic infection was defined as more than one positive test for a given virus with more than 30 days between tests.

Results. Of 932 samples tested, 102 (11%) samples from 48 patients tested positive for norovirus, 15 (2%) samples from 11 patients tested positive for sapovirus, and 16 (2%) samples from 7 patients tested positive for astrovirus. One of these patients had a sample that tested positive for both sapovirus and norovirus, and one tested positive for astrovirus and sapovirus at separate points during the study period. Of the 48 patients with norovirus, 16 (33%) had evidence of chronic infection, with a median duration of 189 days (range 72–372). Of these 16, 14 were known or suspected to be immunodeficient, and 4 had hematologic malignancies. Of 7 patients with astrovirus, 1 (14%) had evidence of chronic infection (132 days). This patient had a hematologic malignancy and was taking immunosuppressive medications. No patients with sapovirus had evidence of chronic infection. Overall, 20 (31%) patients additionally tested positive for another gastrointestinal pathogen, most commonly enteropathic E. coli and C. difficile.

Conclusion. Norovirus remains common in this immunocompromised patient population, and both sapovirus and astrovirus are present. Additional follow-up in this and other cohorts with new molecular tools will enable more complete description of the prevalence, excretion duration, and clinical features of infection with these enteric viruses.

This research was supported by the Intramural Research Program of the NIH, NIAID, and the NIH CC.

Disclosures. All authors: No reported disclosures.

1046. Incidence of Norovirus-Associated Acute Gastroenteritis in Four Veteran’s Affairs Medical Center Populations in the United States, 2011–2015
Scott Grytdal, MPH; Hannah Browne, BS3; Nikkal Collins, BS5; Blanca Vargas, MD; Maria Rodriguez-Barradas, MD, FIDSA4;1, David Beenhouwer, MD1; Sheldon Brown, MD2; Cynthia Lacero-Obusan, MD3; Mark Holodniy, MD, FIDSA, FIDSA, FIDSA;1; Anita Kambhammatti, PharmD,2, Umesh D. Parashar, MBBS1, Jan Viney, PhD6; Benjamin Lopman, PhD2; Aron J. Hall, DVM7; and Cristina V. Cardemil, MD8; National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, 3Infectious Diseases Section, Michael E. DeBakey VA Medical Center, Houston, Texas, 13Infectious Diseases Section, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas, 13Department of Infectious Disease, Department of Medicine, Baylor College of Medicine, Houston, Texas, 13VA Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, 3Mt Sinai School of Medicine, Bronx, New York, 3Public Health Surveillance, VA Greater Los Angeles Healthcare System, and VAMC.

Session: 139. Adult Viral Infection
Friday, October 6, 2017: 12:30 PM

Background. In the USA, norovirus is a common cause of epidemic acute gastroenteritis (AGE) as well as a leading cause of pediatric AGE. However, the burden of sporadic norovirus disease in US adults has not been well-documented. Our objective was to estimate the incidence of outpatient visits and hospitalizations for community-acquired norovirus AGE at four Veterans Affairs Medical Centers (VAMCs) and their associated outpatient clinics in Atlanta, GA; Bronx, New York; Houston, TX; and Los Angeles, CA.

Methods. From November 2011 to September 2015, stool specimens collected for clinician-requested diagnostic testing within 7 days of AGE symptom onset and with reported vomiting or diarrhea were tested for norovirus by real-time RT-PCR and positive samples were genotyped by Sanger sequencing. Incidence of norovirus-associated outpatient visits and hospitalizations were calculated by multiplying the prevalence of norovirus among tested specimens by AGE-coded outpatient encounters and inpatient discharges, and dividing by the unique patients served at each VAMC.

Results. 1,620 stool specimens were tested from all 4 sites. Seven percent of outpatient (n = 795) samples (annual range: 3%–10%; range by site: 3%–10%) and 6% of (n = 220) patients from hospitalized patients tested positive for norovirus (annual range: 3%–8%; range by site: 3%–10%). Forty-four percent of norovirus-positive samples were typed as GIL4 Sydney. Seventy-four percent of norovirus-positive samples were collected between November and April. From 2011 to 2015, outpatient norovirus incidence was 250/100,000 population (annual range: 129 to 426/100,000; range by site: 87 to 428/100,000), and the incidence of norovirus hospitalizations was 28/100,000 population (annual range: 19 to 39/100,000; range by site: 14 to 57/100,000). By age group and setting, the highest incidence was observed in 45- to 64-year-old outpatients (370/100,000 population), and in >65-year-old inpatients (63/100,000 population).

Conclusion. This study provides estimates of the incidence of norovirus AGE outpatient visits and hospitalizations across multiple years among a geographically distributed VA population, highlighting the substantial burden of norovirus in US adults.

Disclosures. All authors: No reported disclosures.

1047. WU Polyomavirus Associated with Severe Respiratory Failure in Children Karishma Uda, MD1; Kensaune Shoji, MD2; Chitose Waki-Boyama, PSc; and Isao Miyairi, MD2; 1Office for Infection Control, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan, 2Infectious Disease, National Center for Child Health and Development, Tokyo, Japan, 3Division of Infectious Diseases, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan

Session: 139. Adult Viral Infection
Friday, October 6, 2017: 12:30 PM

Background. WU polyomavirus (WUPyV) is a relatively new virus associated with respiratory infections. However, its role is unclear in children with severe